ClinicalTrials.gg
RecruitingNCT03132311YF-HIVUpdated Jul 30, 2018

Immunogenicity and Safety of the Yellow Fever Vaccine in HIV Infected Individuals

A Phase 4 interventional study of Yellow Fever vaccination (17 DD Biomanguinhos) in HIV Infections, sponsored by Oswaldo Cruz Foundation. Recruiting at 1 site in Brazil. Open to participants aged 18 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-07-30.

Sponsored by Oswaldo Cruz Foundation · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2018, 7 years 11 months ago, but the record still lists the study as recruiting.
  • Started May 2017; still recruiting 9 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
400
Allocation
Non-randomized
Ages
18 Years to 59 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 142 studies in HIV Infections with a site in Brazil — 12 open to participants now, 17 under way, 5 of them phase 3. HIV Infections · Brazil.

Planned enrollment
51st of 116
400 · median 255
Started
2017
with 4 others
Phase 4
21 of 142
1 open now
Primary completion
2018-12
later than 1 of 16 live
Registered
110th of 142
by date
Lead sponsor
8 of 142
Oswaldo Cruz Foundation

Among the 142 studies in HIV Infections with a site in Brazil, this one is the 51st largest by planned enrollment of the 116 interventional ones that give a count, is one of 5 that started in 2017, is one of 21 in phase 4, reaches primary completion later than 1 of the 16 other live ones, and was the 110th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

12 of the 142 studies in HIV Infections with a site in Brazil are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 59 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies in HIV Infections with a site in Brazil, or all of them as a file.
02

Study summary

Phase 4 study to evaluate the immunogenicity and Safety of the 17DD Yellow Fever vaccine in HIV infected individuals, compared to non-HIV-infected individuals.

Main objective:

To compare the proportion of seroconversion and the geometric mean of neutralizing antibodies 30 days and 365 days after vaccine.

Secondary objectives:

To evaluate whether the titles of neutralizing antibodies are associated with CD4 lymphocyte counts, CD8 lymphocyte counts, CD4 nadir, HIV viral load and use of antiretroviral therapy. To assess the yellow fever vaccine viremia at day 10 after vaccine.To compare the incidence of adverse events in HIV-infected and non-HIV-infected individuals.

03

Conditions studied

  • HIV Infections

Keywords

  • yellow fever vaccine
  • hiv
04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • infected adults, age >= 18 and \<60 years old.
  • > 200 cells/mm³ within the last 6 months prior to inclusion. Individuals with no CD4 results in the last 6 months which have undetectable HIV viral load and last CD4 count > 350 can be included.
  • Healthy HIV-uninfected individuals (aged >= 18 and \< 60)
  • No history of Yellow Fever vaccination
  • Willing to participate and to sign the consent

Exclusion criteria

Exclusion Criteria:

  • Individuals with chronic diseases such as: decompensated diabetes, kidney failure (in dialysis), liver failure/cirrhosis, cancer (except for non-melanoma skin cancer and in situ related carcinoma), use of agents (including prednisone ≥ 20mg/day, during 7 or more days in the last 30 days before inclusion).
  • Pregnant women
  • reaction to eggs, chicken protein. Allergy to erythomycin or kanamycin. Hereditary fructose intolerance.
  • Administration of immunoglobulins or blood derivates \< 3 months or life attenuated vaccine \<1 month.
  • History of thymic dysfunction (including thymoma and thymectomy).
  • Use of anti-CCR5
  • symptoms of severe acute illnesses or fever (axillary temperature ≥ 38°C)
  • HIV positive rapid test for HIV negative subjects.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    HIV positive subjects

    300 HIV positive adults with CD4 \> 200 cells/mm3, stratified in 3 groups (100 patients in each group) according to CD4 counts (200-350; 351-500, \>500 cells/mm3). Assigned intervention: Yellow fever vaccination (17 DD Biomanguinhos)

    Biological: Yellow Fever vaccination (17 DD Biomanguinhos)

  • Active comparator
    HIV negative subjects

    100 HIV negative adults. Assigned intervention: Yellow fever vaccination (17 DD Biomanguinhos)

    Biological: Yellow Fever vaccination (17 DD Biomanguinhos)

Interventions

  • BiologicalYellow Fever vaccination (17 DD Biomanguinhos)

    One intramuscular injection

06

What researchers measure

Primary outcomes

  1. Immunogenicity

    Seroconversion

    Time frame: 30 days after the vaccine

  2. Immunogenicity

    Neutralizing antibodies titers

    Time frame: 30 days after the vaccine

  3. Immunogenicity

    Seroconversion

    Time frame: 365 days after the vaccine

  4. Immunogenicity

    Neutralizing antibodies titers

    Time frame: 365 days after the vaccine

Secondary outcomes

  1. Viremia

    Yellow Fever vaccine viremia

    Time frame: 7 days after the vaccine

  2. Adverse events

    Yellow Fever vaccine related adverse events

    Time frame: up to 30 days after the vaccine

  3. Immunogenicity

    Neutralizing antibodies titles

    Time frame: 5 years after the vaccine

  4. Immunogenicity

    Neutralizing antibodies titles

    Time frame: 10 years after the vaccine

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2017 (actual). Primary completion is estimated for Dec 2018, 19 months after the start.

Of 78 non-industry phase 4 interventional studies under HIV Infections, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 45. This study's planned 19 months is below that.

Counting every sponsor, half of 91 studies reached it within 35 months; a quarter within 23 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2017
First posted
Apr 27, 2017
StartActual
May 29, 2017
Primary completionEst.
Dec 2018
CompletionEst.
Dec 2028
Last update
Jul 30, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03132311
Lead sponsor
Oswaldo Cruz Foundation
Responsible party
Sponsor
First posted
Apr 27, 2017
Start date
May 29, 2017
Primary completion
Dec 2018 (estimated)
Completion
Dec 2028 (estimated)
Last update
Jul 30, 2018

Study contacts

Lara E Coelho, MD
Contact
lara.coelho@ini.fiocruz.br
+552122707064
Beatriz Grinsztejn, MD
Contact
gbeatriz@ini.fiocruz.br
+552122707064

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion